Delandistrogene moxeparvovec-rokl showed significant functional benefits in ambulatory DMD patients compared to external controls in the EMBARK trial. The therapy is the only approved gene therapy for ...
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients "Seeing these promising results validates our ...
Edgewise Therapeutics' valuation is heavily reliant on DMD/BMD programs, with upcoming phase-2 readouts likely to disappoint and trigger a sharp stock decline. We believe that sevasemten's mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results